{
    "clinical_study": {
        "@rank": "31693", 
        "acronym": "FIN-PVI", 
        "arm_group": [
            {
                "arm_group_label": "CABG+Pulmonary vein isolation", 
                "arm_group_type": "Experimental", 
                "description": "Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG"
            }, 
            {
                "arm_group_label": "CABG", 
                "arm_group_type": "Active Comparator", 
                "description": "Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. No operative procedures for the treatment of atrial fibrillation"
            }
        ], 
        "brief_summary": {
            "textblock": "A substantial proportion of patients undergoing elective coronary artery bypass grafting\n      have a history of paroxysmal atrial fibrillation. Paroxysmal atrial fibrillation has adverse\n      short-and long term postoperative effects. Pulmonary vein isolation (PVI) seems to be\n      effective treatment for paroxysmal atrial fibrillation. PVI can be done concomitantly with\n      coronary artery bypass grafting. Procedure is well defined and safe.\n\n      There is a lack of convincing evidence of the effect on postoperative atrial fibrillation\n      burden, quality of life and symptoms especially in correlation with atrial fibrillation\n      paroxysms."
        }, 
        "brief_title": "Surgical Pulmonary Vein Isolation Efficiency Study", 
        "completion_date": {
            "#text": "September 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Paroxysmal Atrial Fibrillation", 
            "Coronary Artery Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  American College of Cardiology (ACC)/ American Heart Association (AHA) -Indications\n             for CABG\n\n          -  At least 2 ECG-verified (12-channel ECG, Holter telemetry) symptomatic paroxysmal\n             atrial fibrillation episodes within last 12 months\n\n          -  Duration of the atrial fibrillation episode must not exceed 1 week and it must\n             reverse to sinus rhythm spontaneously or by cardioversion\n\n          -  written and verbal  consent\n\n        Exclusion Criteria:\n\n          -  Prior cardiac surgery\n\n          -  Active pacemaker treatment\n\n          -  Active anti-arrhythmic treatment(AAD) class I and III\n\n          -  Contraindication to oral anticoagulant/heparin treatment\n\n          -  Ejection fraction less than 30 % (EF < 30 %)assessed by transthoracic\n             echocardiography\n\n          -  Left atrial diameter less than 55mm assessed by transthoracic echocardiography\n\n          -  Renal insufficiency requiring dialysis\n\n          -  Heart valve disease requiring invasive treatment\n\n          -  Heart anomaly requiring regular controls and/or invasive treatment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791218", 
            "org_study_id": "KUH5101071"
        }, 
        "intervention": [
            {
                "arm_group_label": "CABG+Pulmonary vein isolation", 
                "intervention_name": "CABG+pulmonary vein isolation (PVI)", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "CABG", 
                "intervention_name": "CABG", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Pulmonary vein isolation", 
            "Paroxysmal atrial fibrillation", 
            "Quality of life"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kuopio", 
                    "country": "Finland", 
                    "state": "Eastern Finland", 
                    "zip": "70211"
                }, 
                "name": "Kuopio University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Finland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Concomitant Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation Patients Undergoing Elective Coronary Artery Bypass Grafting: a Prospective Study", 
        "overall_contact": {
            "email": "teemu.riekkinen@kuh.fi", 
            "last_name": "Teemu Riekkinen", 
            "phone": "358044175527"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Finland:Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Atrial fibrillation burden is defined as the amount of atrial fibrillation on one week Holter monitoring", 
                "measure": "Atrial fibrillation burden", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }, 
            {
                "description": "Atrial fibrillation is defined as atrial fibrillation paroxysm lasting at least 60 seconds.\nFreedom of atrial fibrillation is defined as duration of atrial fibrillation less than 0,5% of the one week Holter monitoring", 
                "measure": "Freedom of symptomatic and asymptomatic atrial fibrillation after surgery", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Compare quality of life (QOL) and symptoms, correlation of symptoms with atrial fibrillation", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }, 
            {
                "measure": "Adverse events after surgery in both arms", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }, 
            {
                "measure": "Anti-arrhythmic treatment after surgery", 
                "safety_issue": "No", 
                "time_frame": "Within one year after treatment"
            }, 
            {
                "measure": "Hospitalization due to atrial fibrillation after surgery", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }, 
            {
                "measure": "Cardioversion for the treatment of atrial fibrillation after surgery", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }, 
            {
                "measure": "Other cardiovascular related events: death, stroke, cardiac infarction, need for revascularization and bleeding", 
                "safety_issue": "No", 
                "time_frame": "Within one year after operative treatment"
            }
        ], 
        "source": "Kuopio University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kuopio University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}